Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25305166 | 1.00 | TMEM97 (0.44) | TMEM97SIGMAR1CA2TAAR1LMNA | |
| SCHEMBL25303747 | 1.00 | TMEM97 (0.44) | TMEM97SIGMAR1CA2TAAR1LMNA | |
| SCHEMBL3508958 | 0.99 | TMEM97 (0.45) | TMEM97SIGMAR1CA2TAAR1LMNA | |
| SCHEMBL12882864 | 0.94 | TMEM97 (0.42) | TMEM97SIGMAR1CA2TAAR1LMNA | |
| SCHEMBL5606199 | 0.92 | TMEM97 (0.48) | TMEM97SIGMAR1CA2TAAR1LMNA | |
| SCHEMBL2182755 | 0.92 | TMEM97 (0.48) | TMEM97SIGMAR1CA2TAAR1LMNA | |
| SCHEMBL565818 | 0.92 | TMEM97 (0.48) | TMEM97SIGMAR1CA2TAAR1LMNA | |
| SCHEMBL878159 | 0.86 | TMEM97 (0.46) | TMEM97SIGMAR1CA2TAAR1LMNA | |
| SCHEMBL28056762 | 0.86 | SIGMAR1 (0.46) | TMEM97SIGMAR1CA2MEN1KMT2A | |
| SCHEMBL4191243 | 0.86 | TMEM97 (0.46) | TMEM97SIGMAR1CA2TAAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114305-A1 | LIPIDIC COMPOUNDS, AND USES THEREOF | SANOFI (FR) | 2025-04-10 | — | — | US | disclosed |
| EP-4466248-A1 | LIPIDIC COMPOUNDS, AND USES THEREOF | Sanofi (FR) | 2024-11-27 | — | — | EP | disclosed |
| US-20230295097-A1 | LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF | SANOFI PASTEUR (FR) | 2023-09-21 | — | — | US | disclosed |
| US-20230295097-A1 | LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF | SANOFI PASTEUR (FR) | 2023-09-21 | — | — | US | disclosed |
| US-20230293447-A1 | CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF | SANOFI PASTEUR (FR) | 2023-09-21 | — | — | US | disclosed |
| US-20230293447-A1 | CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF | SANOFI PASTEUR (FR) | 2023-09-21 | — | — | US | disclosed |
| WO-2023135305-A1 | LIPIDIC COMPOUNDS, AND USES THEREOF | SANOFI (FR) | 2023-07-20 | — | — | WO | disclosed |
| EP-4182296-A1 | CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF | Sanofi Pasteur (FR) | 2023-05-24 | — | — | EP | disclosed |
| EP-4182302-A1 | LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF | Sanofi Pasteur (FR) | 2023-05-24 | — | — | EP | disclosed |
| WO-2022013443-A1 | LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF | SANOFI PASTEUR (FR) | 2022-01-20 | — | — | WO | disclosed |
| WO-2022013439-A1 | CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF | SANOFI PASTEUR (FR) | 2022-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293447-A1 | CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF | MTTP, CETP, LNPEP | TMEM97 3302/4885SIGMAR1 1580/4885CA2 2229/4885 |
| US-20230295097-A1 | LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF | PRDX5, ANXA5, PRDX1 | TMEM97 2027/4885SIGMAR1 505/4885CA2 2326/4885 |
| US-20250114305-A1 | LIPIDIC COMPOUNDS, AND USES THEREOF | NR1H2, NR1H3, LPAR3 | TMEM97 856/4885SIGMAR1 40/4885CA2 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.